Figure 1. Overall survival (OS) curve according to performance status(PS) of the study cohort of patients with advanced non-small cell lung cancer (mean OS of PS 0= 18.41, PS 1= 10.76, PS
Historical time to disease progression and progression-free survival in patients with recurrent/refractory neuroblastoma treated in the modern era on Children's Oncology Group early-phase trials. - Abstract - Europe PMC
Efficacy of KISQALI® (ribociclib) + AI in Premenopausal | HCP
PSE investigates the correlation between OS and PFS at ESMO 2017
Optimization of PD-L1 algorithm for predicting overall survival (OS) in patients with urothelial cancer (UC) treated with durvalumab monotherapy
A nomogram-based immunoprofile predicts overall survival for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy | Journal for ImmunoTherapy of Cancer | Full Text
IMFINZI® (durvalumab) Efficacy & Clinical Trials for NSCLC
Kaplan-Meier survival curve for overall survival (OS) after total... | Download Scientific Diagram
Exploring the relationship between Overall Survival (OS), Progression Free Survival (PFS) and Objective Response Rate (ORR) in patients with advanced melanoma - ScienceDirect
Difference in median overall survival (OS) (months) of individual therapies per International Classification of Diseases 10th revision (ICD–10) category. - ppt download
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection | PLOS ONE
Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma | British Journal of Cancer
Kaplan-Meier curves for overall survival. OS overall survival, non-MDT... | Download Scientific Diagram
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials | BMJ Open
VENCLEXTA® (venetoclax tablets) | VIALE-A Trial Overall Survival Data
Surrogate endpoints for overall survival in advanced non‑small‑cell lung cancer patients with mutations of the epidermal growth factor receptor gene
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
The overall survival (OS) and progression-free survival (PFS) of patients with tumors involving the subventricular zone (SVZ).
REVEL Trial Overall Survival for | CYRAMZA® (ramucirumab)
1. Why is Overall Survival (OS), in months, | Chegg.com
LENVIMA® (lenvatinib) HCP Website | Overall Survival (OS)
Final overall survival (OS) data from FLAURA trial - YouTube
View Image
Proposal of a Useful Surrogate Endpoint of the Overall Survival in Patients Undergoing Pulmonary Metastasectomy: The Time to Local Therapy Failure | SpringerLink
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
